RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases

Area of Science:

• Molecular Biology
• Immunology
• Oncology

Background:

• The serine/threonine kinase RIPK1 (Receptor-Interacting Protein Kinase 1) is a critical regulator of inflammatory signaling pathways.
• RIPK1 kinase activity is implicated in programmed cell death (apoptosis and necroptosis) and various diseases, including inflammatory, neurodegenerative, and oncogenic conditions.

Purpose of the Study:

• To investigate the role of RIPK1 kinase activity in inflammatory diseases and cancer progression.
• To determine if genetic or pharmacological inhibition of RIPK1 kinase impacts disease severity in preclinical models.

Main Methods:

• Utilized knock-in mice expressing catalytically inactive RIPK1 (RIPK1 D138N) for genetic inhibition.
• Employed the potent murine RIPK1 inhibitor GNE684 for pharmacological inhibition.
• Assessed disease outcomes in models of collagen antibody-induced arthritis, Sharpin-deficient skin inflammation, Nemo-deficient colitis, Kras-driven pancreatic tumors, and B16 melanoma lung metastasis.

Main Results:

• RIPK1 inhibition significantly reduced disease severity in collagen antibody-induced arthritis, Sharpin-deficient skin inflammation, and Nemo-deficient colitis models.
• Conversely, RIPK1 inhibition demonstrated no significant effect on tumor growth, survival in pancreatic cancer models, or lung metastasis in melanoma models.

Conclusions:

• The kinase activity of RIPK1 plays a crucial role in the pathogenesis of specific inflammatory diseases.
• RIPK1 kinase activity appears to be dispensable for tumor progression and metastasis in the investigated cancer models, questioning its broader relevance in oncogenesis.